



## Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

7<sup>th</sup> August, 2017

Corporate Relationship Department  
The BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001.**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
**Bandra (E) Mumbai 400 051.**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

### **Sub:- Outcome of Board Meeting**

We would like to inform you that the Board of Directors of the Company at their meeting held on today have approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30<sup>th</sup> June, 2017 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Review Report of the Statutory Auditors. Please find enclosed a copy of the same for your information.
2. Recommended payment of an interim dividend of Rs.1.25 ps. (62.5%) per equity share of Rs.2/- each for the financial year 2017-18. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. **Record date is fixed for 18<sup>th</sup> August, 2017.** The said interim dividend **pay-by-date is 23<sup>rd</sup> August, 2017.**
3. The date of Annual General Meeting is on 23<sup>rd</sup> September, 2017 and Board had authorised Mr.V.C.Nannapaneni, Chairman and Managing Director for finalizing the time and venue for 34<sup>th</sup> Annual General Meeting for the financial year 2016-17.
4. The Board of Directors also approved Granting of 6,00,000 (six lakh only) Employee Stock options of Rs.2/- each under Natco Employee Stock Option Scheme 2017 (NATSOP 2017) to the eligible employees of the Company and recommended to the members for their approval in the ensuing Annual General Meeting.

Thanking you,

Yours faithfully,  
For NATCO Pharma Limited

M. Adinarayana  
Company Secretary &  
V.P.(Legal & Corp. Affairs)

Encl: as above





## NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.  
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

### STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 June 2017 (Unaudited) (Refer note 4)	31 Mar 2017 (Refer note 3)	30 June 2016 (Unaudited) (Refer note 4)	31 Mar 2017 (Audited)
<b>Revenue</b>				
Revenue from operations	4,453	5,778	3,403	20,650
Other income	34	(6)	52	139
<b>Total revenues</b>	<b>4,487</b>	<b>5,772</b>	<b>3,455</b>	<b>20,789</b>
<b>Expenses</b>				
Cost of materials consumed	1,286	1,010	1,308	5,208
Excise duty	172	131	151	448
Purchases of stock-in-trade	256	56	216	971
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(448)	106	(597)	(188)
Employee benefits expense	631	796	517	2,432
Finance costs	39	64	32	185
Depreciation and amortisation expense	150	135	131	544
Other expenses	1,189	1,268	1,036	4,945
<b>Total expenses</b>	<b>3,275</b>	<b>3,566</b>	<b>2,794</b>	<b>14,545</b>
<b>Profit before tax</b>	<b>1,212</b>	<b>2,206</b>	<b>661</b>	<b>6,244</b>
<b>Tax expense</b>				
Current tax	266	477	167	1,354
Deferred tax	9	(56)	0	1
Tax for earlier years	-	21	19	40
<b>Profit after tax</b>	<b>937</b>	<b>1,764</b>	<b>475</b>	<b>4,849</b>
<b>Other comprehensive income (net of taxes)</b>				
<b>Items that will not be reclassified to profit or loss</b>				
Re-measurement gains/(losses) on defined benefit plans	(8)	(27)	(8)	(50)
Net (loss)/gain on FVTOCI equity securities	7	19	2	28
<b>Items that will be reclassified to profit or loss</b>				
Exchange differences on translation of foreign operations	38	2	-	(12)
<b>Total comprehensive income</b>	<b>974</b>	<b>1,758</b>	<b>469</b>	<b>4,815</b>
<b>Profit attributable to:</b>				
Owners of the parent	940	1,767	477	4,860
Non-controlling interests	(3)	(3)	(2)	(11)
<b>Total comprehensive income attributable to:</b>				
Owners of the parent	977	1,761	471	4,826
Non-controlling interests	(3)	(3)	(2)	(11)
<b>Paid-up equity share capital of ₹2 each</b>	<b>349</b>	<b>349</b>	<b>348</b>	<b>349</b>
<b>Other equity</b>				<b>16,144</b>
<b>Earnings per share (non-annualised)</b>				
Basic	5.59	10.10	2.74	27.78
Diluted	5.58	10.09	2.73	27.75





## NATCO Pharma Limited

### Notes to the consolidated results:

1. The Company adopted Indian Accounting Standard ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
2. The consolidated financial results for the quarter ended 30 June 2017 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 7 August 2017.
3. The figures of the quarter ended 31 March 2017 are the balancing figures between audited figures in respect of full financial year ended 31 March 2017 and the unaudited published year to date figures upto 31 December 2016 which were subjected to limited review.
4. The results for the quarter ended 30 June 2017 and 30 June 2016 presented were subjected to a limited review by the statutory auditors of the Company.
5. The Group operates in one reportable segment which is "Pharmaceuticals".
6. The Board of Directors at their meeting held on 7 August 2017 have recommended an interim dividend of ₹1.25 per equity share of ₹2 each for the current financial year.

By Order of the Board

  
V.C. Nannapaneni  
Chairman and Managing Director

Hyderabad  
7 August 2017



# Walker Chandiook & Co LLP

**Walker Chandiook & Co LLP**  
(Formerly Walker, Chandiook & Co)  
7th Floor, Block III, White House  
Kundan Bagh, Begumpet  
Hyderabad 500016  
India

T +91 40 6630 8200  
F +91 40 6630 8230

## **Independent Auditor's Review Report on Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### **To the Board of Directors of NATCO Pharma Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results for the quarter ended 30 June 2017 ('the Statement') of NATCO Pharma Limited ('the Company') and its subsidiaries (the Company and its subsidiaries together referred to as 'the Group'), (Refer Annexure 1 for the list of subsidiaries included in the Statement), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above and upon consideration of the review reports of the other auditors, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurgaon, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

# Walker Chandiook & Co LLP

## Independent Auditor's Review Report on Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Cont'd)

4. We did not review the financial results of six subsidiaries included in the Statement whose financial results reflect total revenues of ₹152 million for the quarter ended 30 June 2017 and net loss of ₹37 million for the quarter ended 30 June 2017. These financial results have been reviewed by other auditors whose review reports have been furnished to us by the management and our report in respect thereof is based solely on the review reports of such other auditors.

Further, all of the above mentioned six subsidiaries are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial results of such subsidiaries outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our report in so far as it relates to the financial results of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and reviewed by us.

Our review report is not modified in respect of these matters.

*Walker Chandiook & Co LLP*

**For Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No: 001076N/N500013

*Adi P. Sethna*  
per **Adi P. Sethna**  
Partner  
Membership No.: 108840



Place: Hyderabad  
Date: 7 August 2017

# Walker Chandniok & Co LLP

**Independent Auditor's Review Report on Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Cont'd)**

## **Annexure 1**

### **List of entities included in the Statement**

- (a) NATCO Pharma, Inc.
- (b) Time Cap Overseas Limited
- (c) NATCO Farma Do Brasil LTDA (subsidiary of Time Cap Overseas Limited)
- (d) NATCO Pharma (Canada) Inc.
- (e) NATCO Pharma Asia Pte. Ltd.
- (f) NATCO Pharma Australia PTY Ltd.





## NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034  
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

### STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 June 2017 (Unaudited) (Refer note 4)	31 March 2017 (Refer note 3)	30 June 2016 (Unaudited) (Refer note 4)	31 March 2017 (Audited)
<b>Revenue</b>				
Revenue from operations	4,308	5,553	3,246	20,028
Other income	27	(8)	48	132
<b>Total revenues</b>	<b>4,335</b>	<b>5,545</b>	<b>3,294</b>	<b>20,160</b>
<b>Expenses</b>				
Cost of materials consumed	1,286	1,010	1,308	5,208
Excise duty	172	131	151	448
Purchases of stock-in-trade	187	7	93	687
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(447)	106	(597)	(167)
Employee benefits expenses	603	757	495	2,321
Finance costs	38	59	30	175
Depreciation and amortisation expense	148	132	130	536
Other expenses	1,101	1,129	989	4,611
<b>Total expenses</b>	<b>3,088</b>	<b>3,331</b>	<b>2,599</b>	<b>13,819</b>
<b>Profit before tax</b>	<b>1,247</b>	<b>2,214</b>	<b>695</b>	<b>6,341</b>
<b>Tax expense</b>				
Current tax	266	477	167	1,353
Deferred tax	7	(58)	0	-
Tax for earlier years	-	22	19	40
<b>Profit after tax</b>	<b>974</b>	<b>1,773</b>	<b>509</b>	<b>4,948</b>
<b>Other comprehensive income (net of taxes)</b>				
<b>Items that will not be reclassified to profit or loss</b>				
Re-measurement gains/(losses) on defined benefit plans	(8)	(27)	(8)	(50)
Net gain/(loss) on FVTOCI equity securities	6	19	2	28
<b>Total comprehensive income</b>	<b>972</b>	<b>1,765</b>	<b>503</b>	<b>4,926</b>
<b>Paid-up equity share capital of ₹2 each</b>	<b>349</b>	<b>349</b>	<b>349</b>	<b>349</b>
<b>Other equity</b>				<b>16,648</b>
<b>Earnings per share (non-annualised)</b>				
Basic	5.58	10.13	2.92	28.27
Diluted	5.56	10.11	2.91	28.24





## NATCO Pharma Limited

### Notes to the standalone results:

1. The Company adopted Indian Accounting Standard ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
2. The standalone financial results for the quarter ended 30 June 2017 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 7 August 2017.
3. The figures of the quarter ended 31 March 2017 are the balancing figures between audited figures in respect of full financial year ended 31 March 2017 and the unaudited published year to date figures upto 31 December 2016 which were subjected to limited review.
4. The results for the quarter ended 30 June 2017 and 30 June 2016 presented were subjected to a limited review by the statutory auditors of the Company.
5. The Company operates in one reportable segment which is "Pharmaceuticals".
6. The Board of Directors at their meeting held on 7 August 2017 have recommended an interim dividend of ₹1.25 per equity share of ₹2 each for the current financial year.

By Order of the Board



V.C. Nannapaneni  
Chairman and Managing Director

Hyderabad  
7 August 2017





# Walker Chandiook & Co LLP

**Walker Chandiook & Co LLP**  
(Formerly Walker, Chandiook & Co)  
7th Floor, Block III, White House  
Kundan Bagh, Begumpet  
Hyderabad 500016  
India

T +91 40 6630 8200  
F +91 40 6630 8230

## **Independent Auditor's Review Report on Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### **To the Board of Directors of NATCO Pharma Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results for the quarter ended 30 June 2017 ('the Statement') of NATCO Pharma Limited ('the Company'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# Walker Chandiok & Co LLP

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*Walker Chandiok & Co LLP*

**For Walker Chandiok & Co LLP**

Chartered Accountants

Firm Registration No: 001076N/N500013



per **Adi P. Sethna**

Partner

Membership No.: 108840



Place: Hyderabad

Date: 7 August 2017